about
Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virusAssembly and release of infectious hepatitis C virus involving unusual organization of the secretory pathwayStructure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2Hepatitis C.Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designContradictory immune response in post liver transplantation hepatitis B and C.Immune control and failure in HCV infection--tipping the balance.The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development.Designing and Development of a DNA Vaccine Based On Structural Proteins of Hepatitis C VirusSeveral Human Liver Cell Expressed Apolipoproteins Complement HCV Virus Production with Varying Efficacy Conferring Differential Specific Infectivity to Released VirusesAdaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.Heterologous Immunity between Adenoviruses and Hepatitis C Virus: A New Paradigm in HCV Immunity and Vaccines.Spouse-to-Spouse Transmission and Evolution of Hypervariable Region 1 and 5' Untranslated Region of Hepatitis C Virus Analyzed by Next-Generation SequencingNetwork Analysis of the Chronic Hepatitis C Virome Defines Hypervariable Region 1 Evolutionary Phenotypes in the Context of Humoral Immune Responses.Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C VirusThe ins and outs of hepatitis C virus entry and assembly.How hepatitis C virus invades hepatocytes: the mystery of viral entryImmune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.HCV glycoprotein structures: what to expect from the unexpected.Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies.Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.Antigenic Drift Defines a New D4 Subgenotype of Measles Virus.Non-neutralizing epitopes induce robust hepatitis C virus (HCV)-specific antibody-dependent CD56+ natural killer cell responses in chronic HCV-infected patients.Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors In Vitro and Ex Vivo.Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.Innate and Adaptive Immune Responses in Chronic HCV Infection.The unexpected structures of hepatitis C virus envelope proteinsViral hepatitis: Cell-culture-derived HCV--a promising vaccine antigen.Screening HCV genotype-specific epitope peptides based on conserved sequence analysis and B cell epitope prediction in HCV E2 region.Hepatitis C Virus Envelope Glycoproteins: A Balancing Act of Order and Disorder
P2860
Q26783378-85FDDC7D-64B9-40D7-BE4F-49EB8849ABA1Q27468952-84A07066-521F-4C6E-B8A4-4323DBD43558Q27681839-53E4C69C-1C85-4E34-863F-F0A4354FD653Q28084654-2633BDAD-AD00-4C01-8724-59B36D899ECEQ30374314-502EC945-7974-4444-9967-F87933F352EAQ34152074-AECD732E-D2C6-459D-B6C3-6683666D250AQ34178628-1641DF87-1B22-47E1-AB72-68E343F783B1Q34481429-2A3279A0-8B6C-4607-9543-0ACF5C6C974FQ34543833-CC932667-6FA1-4E0D-95B5-B930F03FEFDAQ35727227-2A215076-678D-4AFB-AABD-A81037AB0BAAQ35861270-593FE590-DADB-4ED3-B584-A290E853FE9FQ35889892-D7F2BD12-6BC2-44EC-928C-DD6C6743B41BQ35936933-35E025EA-E53B-453B-BF2A-360E9943FBC2Q36694134-7C3C6684-C5FA-4481-880F-BA97FD7AFE32Q37252935-CED45B3E-7328-43C6-9AA2-18885162842FQ37498626-1B329B7E-E94C-416B-BFB8-20CE0C327C68Q37682499-F8B10A8B-CDA7-4F48-8594-262535098692Q38334024-2C35E5C1-06D9-4A3A-8B0C-6811A55847C3Q38384140-D26C01D0-AE4C-4C2D-8579-57AECD36FB37Q38715557-E2B9D8E2-8006-4BA3-85D6-42F23019B901Q38805093-A50EC4EE-F4DE-49EC-B17E-03F8281E0895Q40267862-8E2CBA33-44AA-41F6-8119-34861D8904F5Q40286085-18072D7B-CB5B-4739-A4C5-F76210950AD7Q40334457-1296DB6B-E356-4A8C-9CEF-1E020C27B26CQ40634075-0B9C65C5-E48A-4B2F-9515-464029D81912Q41035955-85AF573F-0D55-4DFB-AC4C-B70E6E24F116Q41672624-E915E597-8955-4E02-864A-1B65C140C578Q45783350-37CA4B2D-E942-4AFC-A602-A422DC408113Q47335897-B1365600-3FDB-4A6E-B79C-A10F5E871F57Q57265415-D923AAC9-E022-43C2-B35C-A5E561F9DAF5
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Virus-neutralizing antibodies to hepatitis C virus.
@en
type
label
Virus-neutralizing antibodies to hepatitis C virus.
@en
prefLabel
Virus-neutralizing antibodies to hepatitis C virus.
@en
P2860
P356
P1476
Virus-neutralizing antibodies to hepatitis C virus.
@en
P2860
P304
P356
10.1111/JVH.12094
P577
2013-04-04T00:00:00Z